Dr. Anne Covey on Locoregional Therapy in Hepatocellular Carcinoma
Anne Covey, MD, discusses options for patients with hepatocellular carcinoma (HCC) who cannot undergo resection or transplant.
Anne Covey, MD, interventional radiologist, Memorial Sloan Kettering Cancer Center, discusses options for patients with hepatocellular carcinoma (HCC) who cannot undergo resection or transplant. Covey says this group of patients is around 80% of those diagnosed with HCC, and the most common form of therapy is locoregional treatment, or therapy targeted to the liver.
Covey says some beneficial locoregional therapies offered to patients with HCC are bland embolization, chemoembolization, radioembolization, embolization with drug-eluding beads, and ablation.
Gasparetto Explains Rationale for Quadruplet Front Line in Transplant-Ineligible Myeloma
February 22nd 2025In a Community Case Forum in partnership with the North Carolina Oncology Association, Cristina Gasparetto, MD, discussed the CEPHEUS, IMROZ, and BENEFIT trials of treatment for transplant-ineligible newly diagnosed multiple myeloma.
Read More
Key Trials From ASH 2024 Impact Treatment for Plasma Cell Disorders Going Forward
February 20th 2025Peers & Perspectives in Oncology editorial board member Marc J. Braunstein, MD, PhD, FACP, discussed the significant advancements in multiple myeloma treatment at the 2024 ASH Annual Meeting and Exposition.
Read More
